The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive ...

The SELECTION study1 showed that the JAK 1 inhibitor filgotinib is safe and efficacious in ulcerative colitis. Based on positive results of the phase 2 FITZROY study2 in Crohn's disease, it was ...

The chronic condition can cause abdominal pain, diarrhea, bloody stools and fatigue. New research suggests it affects more ...

A study reveals a sharp rise in inflammatory bowel disease (IBD) among American youth, with over 100,000 under 20 affected.

In fact, as many as 35% of people with IBD have some kind of oral manifestation of the condition, such as canker sores, the ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

Inflammatory bowel disease (IBD) affects an estimated 1.6 million Americans. In fact, there are more than 70,000 new cases of ...

Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring ...

Evaluating colitis treatment efficacy and body composition changes using an IL-12/23 p40 neutralizing antibody, measured ...

Learn about the new guidelines released by the AGA for pharmacological management of moderate-to-severe ulcerative colitis.

Clinical trials are necessary for finding new ways of preventing, detecting or treating diseases, but often, limited ...

Dr. Raymond Cross of Mercy Medical Center joins Jennifer Franciotti for a conversation about ulcerative colitis - how it ...